MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?
The American Journal of Emergency Medicine · 2024
DOI: 10.1016/j.ajem.2024.06.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Emergency Medicine, 2024. Verfasst von Murat Sütçü und 7 weiteren Autor:innen. Beteiligte Einrichtung: Istinye University Faculty of Medicine, Bahçeşehir Liv Hospital, Department of Pediatric Infectious Diseases, Istanbul, Turkey. Hauptthemen laut MEDLINE: Glucocorticoids, Systemic Inflammatory Response Syndrome, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The effectiveness of using only glucocorticoids (GCs) in mild multisystem inflammatory syndrome (MIS-C) cases was compared with combined treatment [GCs + Intravenous immune globulin (IVIG)]. METHODS: This retrospective cohort study was conducted between June 1, 2020, and June 1, 2022, in a tertiary care center in Istanbul, Turkey. Clinical and investigational data of the MIS-C patients were analyzed. The patients were divided into two groups: those who received only GCs and those who received the GCs + IVIG combination. The primary outcome focused on assessing the deterioration of the patient's clinical condition, the occurrence of shock, admission to the pediatric intensive care unit (PICU), and the need for additional immunosuppressive medication. Secondary outcomes included evaluating the course of cardiovascular and infection-related complications observed at the one-year follow-up. RESULTS: Ninety-seven MIS-C patients with a median age of 41 (3- 214) months were enrolled. Fifty-six (57.7%) patients were male. All the patients had fever at admission with a temperature of 39 °C (37.5 °C-40.1 °C). Thirty-two patients (33%) had cardiac findings on echocardiography [left ventricular dysfunction (n= 13, 13.5%), coronary artery involvement (n= 11, 11.3%), and dilation of cardiac cavities and/or increased cardiac muscle thickness (n= 8, 8.2%)]. Thirteen patients (13.5%) required intensive care. All patients received GCs [only GCs (group I; n= 65, 67%)], and 32 patients (33%) with severe manifestations and/or cardiac involvement received GCs + IVIG (group II). No mortality was observed. None of the patients had any complaints at the one-year follow-up, and all echocardiography findings were normal. CONCLUSION: This study provides preliminary evidence that GC monotherapy is a safe treatment alternative for mild MIS-C cases without cardiac involvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istinye University Faculty of Medicine, Bahçeşehir Liv Hospital, Department of Pediatric Infectious Diseases, Istanbul, Turkey.
- Yeditepe University Faculty of Medicine, Department of Pediatric Infectious Diseases, Istanbul, Turkey.
- Istinye University Faculty of Medicine, Bahçeşehir Liv Hospital, Department of Pediatrics, Istanbul, Turkey.
- Basaksehir Cam Sakura Training and Research Hospital, University of Health Sciences, Department of Pediatric Emergency, Turkey.
- Yeditepe University Faculty of Medicine, Department of Pediatrics, Istanbul, Turkey. Electronic address: md.duyguyilmaz@gmail.com.
- Istinye University Faculty of Medicine, Bahçeşehir Liv Hospital, Department of Pediatric Cardiology, Istanbul, Turkey.
Zitieren
APA
Sütçü, M., Kara, E. M., Yıldız, F., Gül, D., Yıldız, R., Yılmaz, D., Atik, F., & Özkaya, O. (2024). MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?. The American Journal of Emergency Medicine. https://doi.org/10.1016/j.ajem.2024.06.030
Vancouver
Sütçü M, Kara EM, Yıldız F, Gül D, Yıldız R, Yılmaz D, et al. MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?. The American Journal of Emergency Medicine. 2024. doi:10.1016/j.ajem.2024.06.030
BibTeX
@article{St2024,
author = {Sütçü, Murat and Kara, Emine Manolya and Yıldız, Funda and Gül, Doruk and Yıldız, Raif and Yılmaz, Duygu and Atik, Fatih and Özkaya, Ozan},
title = {MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?},
journal = {The American Journal of Emergency Medicine},
year = {2024},
doi = {10.1016/j.ajem.2024.06.030}
}
EUVIMED